Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News


BARD1 Life Sciences - Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test



-- POC achieved in feasibility studies demonstrating that a SubB2M/CA125 ELISA can detect the CA125 biomarker for ovarian cancer in patient samples
-- SubB2M/CA125 ELISA-based test detects CA125-Neu5Gc, making it highly specific for CA125 from ovarian cancer
-- Achievement of this key POC milestone supports and de-risks advancing the development of SubB2M ELISA tests for ovarian, breast, prostate and other cancers

Melbourne, Australia, 17 August 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that proof-of-concept (POC) has been achieved for its SubB2M/CA125 enzyme-linked immunosorbent assay (ELISA)-based test for ovarian cancer. BARD1’s collaborator, the Institute for Glycomics at Griffith University (Griffith), has demonstrated that an initial SubB2M/CA125 assay can detect CA125-Neu5Gc in serum from stages I-IV ovarian cancer (OC) patients compared to healthy controls at biologically relevant levels.

Previous research by the Griffith research team led by Professor Mike Jennings showed that a SubB2M surface plasmon resonance (SPR)-based assay that measures binding of SubB2M to the cancer biomarker Neu5Gc, could detect elevated Neu5Gc at all-stages of OC with 100% sensitivity and specificity compared to healthy controls. BARD1 initiated a development program in December 2020 to transfer the cancer biomarker SPR-assay to cancer-specific ELISA-based tests that combined tissue-specific cancer biomarkers such CA125 for OC, CA15-3 for breast cancer and PSA for prostate cancer. ELISA is a common and low-cost assay format that can be performed in commercial laboratories worldwide, including on high throughput laboratory instrumentation. Development of a SubB2M/CA125 ELISA-based test has the potential to create an accurate, reliable, and affordable test for monitoring and early detection of OC.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.